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PARKINSON\'S DISEASE (PD) is a neurodegenerative disorder characterized by a range of motor and nonmotor features such as resting tremor, bradykinesia, rigidity, postural instability, and neurobehavioral dysfunction.[1](#jmri26887-bib-0001){ref-type="ref"} Clinically heterogeneous phenotypes and variable progression in PD suggest complex underlying microstructural alterations involving multiple brain regions and different networks beyond the nigrostriatal pathway.[2](#jmri26887-bib-0002){ref-type="ref"}, [3](#jmri26887-bib-0003){ref-type="ref"}, [4](#jmri26887-bib-0004){ref-type="ref"} Focal gray matter lesions within the basal ganglia and iron deposition also contribute to the pathophysiology of PD.[5](#jmri26887-bib-0005){ref-type="ref"}, [6](#jmri26887-bib-0006){ref-type="ref"}, [7](#jmri26887-bib-0007){ref-type="ref"} Postural instability gait disorder (PIGD), a motor subtype of PD with predominant balance and gait disturbances, progresses rapidly, with prominent cognitive decline, and has been postulated to be secondary to complication by periventricular leukoaraiosis.[8](#jmri26887-bib-0008){ref-type="ref"} In addition, PIGD patients are less responsive to levo‐dopamine treatment[9](#jmri26887-bib-0009){ref-type="ref"} compared with the tremor dominant PD subtype. Hence, distinguishing the PIGD motor subtype of PD for early intervention and therapeutic management is important.

Morphometric brain studies reporting structural alterations between PD subtypes are typically voxel‐based, semiautomated,[4](#jmri26887-bib-0004){ref-type="ref"}, [10](#jmri26887-bib-0010){ref-type="ref"}, [11](#jmri26887-bib-0011){ref-type="ref"} and yield inconsistent findings of cortical and subcortical volume alterations.[10](#jmri26887-bib-0010){ref-type="ref"}, [11](#jmri26887-bib-0011){ref-type="ref"}, [12](#jmri26887-bib-0012){ref-type="ref"}, [13](#jmri26887-bib-0013){ref-type="ref"} None have examined deep gray nuclear lesion load to date.[4](#jmri26887-bib-0004){ref-type="ref"}, [14](#jmri26887-bib-0014){ref-type="ref"} This study aimed at evaluating the utility of 1) a fully automated volume‐based morphometry, and 2) novel deep gray nuclear lesion load estimation (GMab) in characterizing imaging diagnostic markers in PD and PIGD in relation to clinical correlates. This was then applied to 3) construct a model that could discriminate the PIGD subtype to aid in classification.

Materials and Methods {#jmri26887-sec-0013}
=====================

*Study Subjects* {#jmri26887-sec-0014}
----------------

This prospective study was conducted in accordance with approved guidelines and regulations of the Institutional Review Board. Informed consent was obtained from all subjects. Sixty‐six subjects (25 PIGD, 21 PD, and 20 age‐ and gender‐matched controls) were included in this automated whole‐brain morphometric analysis.[15](#jmri26887-bib-0015){ref-type="ref"}, [16](#jmri26887-bib-0016){ref-type="ref"} Diagnosis was made by a movement disorders neurologist (E.T.) with more than two decades of clinical experience in the field, following the United Kingdom PD Brain Bank criteria.[17](#jmri26887-bib-0017){ref-type="ref"} PIGD is diagnosed based on the widely used clinical classification of the ratio of the mean Unified Parkinson\'s Disease Rating Scale Motor Scale (UPDRS) tremor to PIGD scores (≤1.0).[1](#jmri26887-bib-0001){ref-type="ref"}, [18](#jmri26887-bib-0018){ref-type="ref"} Disease severity was evaluated in the \"on state\" using UPDRS Part III[19](#jmri26887-bib-0019){ref-type="ref"} and modified Hoehn and Yahr Scale.[20](#jmri26887-bib-0020){ref-type="ref"} Motor symptoms were assessed using the Tinetti Balance Scale (TBS).[21](#jmri26887-bib-0021){ref-type="ref"} No lateralization of motor symptoms was reported. The Abbreviated Mental Test[22](#jmri26887-bib-0022){ref-type="ref"} was used to screen for cognitive dysfunction. Vascular risk factors, namely hypertension, diabetes, and hyperlipidemia, were recorded.

Exclusion criteria included secondary Parkinsonism, parkinsonism‐plus syndromes,[17](#jmri26887-bib-0017){ref-type="ref"} atypical parkinsonism features (suggesting stroke, normal pressure hydrocephalus, or structural lower limb abnormalities), cognitive and organ dysfunction or life‐threatening diseases. Secondary parkinsonism refers to symptomatic parkinsonism secondary to other causes such as drug‐induced parkinsonism, space‐occupying or infective etiologies, whereas parkinson‐plus syndromes refer to rapidly progressive neurodegenerative conditions presenting with parkinsonism and additional neurological abnormalities such as autonomic dysfunction, cerebellar, and eye signs. The patients included in our cohort had a follow‐up period of at least 3 years at our Movement Disorders clinics to reduce misdiagnosis and exclude parkinson‐plus syndromes. Controls were recruited from healthy volunteers and relatives of patients with no evidence of neurological disorders or cognitive dysfunction.

*MRI Acquisition* {#jmri26887-sec-0015}
-----------------

Magnetic resonance imaging (MRI) brain imaging was performed on a 3T MR scanner (Magnetom Trio, Siemens Healthcare, Erlangen, Germany) with a 12‐channel phased array head coil. Sagittal 3D‐magnetization‐prepared rapid gradient echo (MPRAGE) parameters were: repetition time / echo time / inversion time / flip angle (TR/TE/TI/FA) 2200/3.0/900msec/9 degrees; 240 mm field of view (FOV); 256 × 256 matrix; 0.9 mm slice thickness; 192 slices. A fluid‐attenuated inversion recovery imaging (FLAIR) sequence (TR/TE 5000/384 msec; 230 mm FOV; 256 × 256 matrix; 0.9 slice thickness; 192 slices) was used to aid in quality review of abnormal white and gray matter segmentation. Subjects\' heads were stabilized with foam padding on both sides. Patients were scanned during their \"on\" state to reduce motion.

*Image Analysis* {#jmri26887-sec-0016}
----------------

Automated segmentation of deep gray nuclei, ie, caudate, thalamus, putamen, and pallidum, was performed using the MorphoBox prototype combining atlas‐based segmentation and atlas‐free tissue classification algorithms.[23](#jmri26887-bib-0023){ref-type="ref"}, [24](#jmri26887-bib-0024){ref-type="ref"} Figure [1](#jmri26887-fig-0001){ref-type="fig"}a--c shows a representation of the processing performed to estimate abnormal white matter (WMab) and deep gray nuclear lesion load (GMab) volumes. Brain tissue classification was performed on a skull‐stripped brain by means of a template‐free algorithm fitting a 5‐class Gaussian mixture model roughly representing ventricular cerebrospinal fluid (CSF), sulcal CSF, cortical gray matter, deep gray matter, and white matter. Model fitting was carried out using a variational expectation‐maximization algorithm,[24](#jmri26887-bib-0024){ref-type="ref"} which generated an output of five a posteriori probability maps and subsequently converted into three maps corresponding to CSF, gray matter, and white matter by combining the ventricular with sulcal CSF maps and the cortical with deep gray matter maps. WMab was detected by thresholding the difference between posterior and prior white matter probability maps[23](#jmri26887-bib-0023){ref-type="ref"} according to a constant value of 0.6. GMab was obtained by summing up CSF a posteriori probabilities over each nucleus mask obtained by atlas propagation.

![MorphoBox processing pipeline **(a)** generating a posteriori probability maps and volumetry, estimating **(b)** WMab volume and **(c)** putamen GMab (eg), **(d)** illustrative segmentation masks overlaid on axial T~1~‐MPRAGE images of representative PIGD, PD, and HC subjects.](JMRI-51-748-g001){#jmri26887-fig-0001}

### *Computation of WMab and GMab* {#jmri26887-sec-0017}

WMab is a relative volumetric measure, where $\text{WMab} = \frac{\text{Abnormal\ white\ matter\ volume}}{\text{Total\ whole\ brain\ gray\ matter\ and\ white\ matter\ probabilities}\ }$. For each deep gray nucleus, absolute volume for each is first computed by summing up gray and white matter probabilities over relevant anatomical masks, eg, . Relative deep gray nuclear volume is then normalized over total brain volume, eg, $\text{caudate\ volumetry} = \frac{\text{Absolute\ caudate\ volume}}{\text{Total\ whole\ brain\ gray\ matter\ and\ white\ matter\ probabilities}\ }$. Tissue composition of each deep gray nucleus is also computed, eg, $\text{caudate\ gray\ matter} = \frac{\text{Absolute\ volume\ of\ gray\ matter\ probabilities\ in\ caudate}}{\text{Absolute\ caudate\ volume}}$ and $\text{caudate\ white\ matter} = \frac{\text{Absolute\ volume\ of\ white\ matter\ probabilities\ in\ caudate}}{\text{Absolute\ caudate\ volume}}$. GMab is obtained by summing up CSF a posteriori probabilities over each nucleus, eg, $\text{caudate\ GMab} = \frac{{Sum}\ \text{of}\ {CSF}\ a\ \text{posteriori\ probabilities\ in\ caudate}}{\text{Absolute\ caudate\ volume}}$.

All segmentation masks were reviewed using ITK‐Snap.[25](#jmri26887-bib-0025){ref-type="ref"} WMab and GMab segmentation was assessed with corresponding FLAIR images of each subject. Quality of the segmentation masks for each subject was independently assessed by two authors (E.F. and C.A.) with about 3 years of experience. When discrepant, consensus was reached with a third reviewer (L.C.) with more than two decades of neuroradiological experience.

*Statistical Analysis* {#jmri26887-sec-0018}
----------------------

Data analysis was performed using R v. 3.4.1 (Vienna, Austria). One‐way analysis of variance (ANOVA) on ranks controlling for age and gender with Bonferroni‐corrected pairwise comparisons was used to assess significant brain segmentation and clinical parameter differences across subgroups. As aforementioned, estimated volumes were summed over both hemispheres and then normalized by total brain volume to correct for atrophy, prior to intersubject comparisons. Univariate regression was performed to determine the dependence of TBS and UPDRS scores on brain segmentation variables while controlling for age and gender. After variable selection by stepwise regression, a multiple linear regression model, controlled for age and gender, was utilized to assess the relationship between extracted volumetry and clinical scores. Additionally, logistic regression was performed to differentiate PIGD from PD, and discriminative reliability was evaluated using receiver operating characteristics (ROC) analysis. Statistically significant variables from univariate analysis were converted to indicator variables to form the initial variable set, with forward selection performed to construct the full model in ROC analysis. Unless otherwise stated, statistical significance was defined at *P* \< 0.05.

Results {#jmri26887-sec-0019}
=======

Table [1](#jmri26887-tbl-0001){ref-type="table"} summarizes the demographics and clinical characteristics of subjects included in the final analysis. Two PIGD patients were excluded due to significant misclassification of GMab in the striatum. Figure [1](#jmri26887-fig-0001){ref-type="fig"}d illustrates representative images demonstrating the segmentation output and labeling of both WMab and GMab.

###### 

Summarized Demographics and Clinical Characteristics

  Total included *N* = 64      PIGD *N* = 23   PD N = 21    HC N = 20    *P*‐value
  ---------------------------- --------------- ------------ ------------ ---------------------------------------------------
  Age (years)                  72.87 5.69      71.95 4.80   71.45 4.89   0.42
  Range (years)                63\~82          62\~82       62\~80       
  Gender (*n*)                                                           
  Male                         17              17           16           0.89[+](#jmri26887-note-0005){ref-type="fn"}
  Female                       6               4            4            
  AMT                          9.13 0.16       9.38 0.17    9.55 0.17    0.21
  H&Y                          2.76 0.12       2.24 0.12                 \<0.01
  TBS                                                                    
  Total                        16.22 0.83      19.86 0.87   26.65 0.89   \<0.01[\*\*](#jmri26887-note-0007){ref-type="fn"}
  Balance                      9.35 0.53       11.24 0.56   15.25 0.57   \<0.01[\*](#jmri26887-note-0006){ref-type="fn"}
  Gait                         6.91 0.40       8.62 0.42    11.40 0.43   \<0.01[\*\*](#jmri26887-note-0007){ref-type="fn"}
  UPDRS                                                                  
  Total                        43.30 2.96      40.62 3.10                0.53
  Tremor                       0.43 0.79       4.62 0.83                 \<0.01
  Nontremor                    23.04 1.35      18.29 1.41                0.02
  Vascular risk Factor (*n*)                                             
  Diabetes                     9               5            3            0.19
  Hypertension                 11              12           12           0.70
  Heart disease                6               3            1            0.18[+](#jmri26887-note-0005){ref-type="fn"}
  Hypercholesterolemia         9               9            6            0.68

Values shown as mean SE, except for age (SD). *P*‐values derived from one‐way ANOVA between‐subjects, except for gender and vascular risk factor, which were tested using chi‐square test of independence.

AMT = Abbreviated Mental Test; H&Y = Hoehn and Yahr Stage Scale; TBS = Tinetti Balance Scale; UPDRS = Unified Parkinson Disease Rating Scale. PIGD = postural instability gait disorder; PD = Parkinson\'s disease; HC = healthy controls

*P*‐value was based on 1000 bootstrapped to correct for cell frequency \< 5.

Pairwise comparison after Bonferroni correction were statistically significant (*P* \< 0.05), except for PIGD and PD (*P* = 0.05).

All pairwise comparison after Bonferroni correction were statistically significant (*P* \< 0.05)

Table [2](#jmri26887-tbl-0002){ref-type="table"} details the volumetric comparison of the structures of interest and statistical comparisons between the PIGD, PD, and HC after Bonferroni correction. Lobar analyses (namely, frontal, parietal, temporal, and occipital) of cortical gray matter and white matter volumetry demonstrated no significant differences between PIGD, PD, and healthy controls (HC), and are not included. Structural volumetry that were significantly different across the groups are graphically depicted in Fig. [2](#jmri26887-fig-0002){ref-type="fig"}a,b.

###### 

Volumetric Comparison of Selected Structures With *P*‐Values for Post‐Hoc Bonferroni‐Corrected Comparisons Between the PIGD, PD, and HC

  Structure                   PIGD            PD              Controls        F‐value (P‐value)   PIGD vs. PD   PIGD vs. HC   PD vs. HC
  --------------------------- --------------- --------------- --------------- ------------------- ------------- ------------- -----------
  Total‐intracranial volume   1.000           1.000           1.000           ---                 ---           ---           ---
  CSF                         0.315 ± 0.005   0.295 ± 0.005   0.282 ± 0.005   11.945 (0.000)      0.014         \<0.001       n.s
  Lateral Ventricles          0.053 ± 0.003   0.039 ± 0.003   0.032 ± 0.003   10.867 (0.000)      0.006         \<0.001       n.s
  3^rd^ Ventricle             0.003 ± 0.000   0.003 ± 0.000   0.003 ± 0.000   7.104 (0.002)       0.029         0.002         n.s
  4^th^ Ventricle             0.003 ± 0.000   0.002 ± 0.000   0.002 ± 0.000   5.828 (0.005)       n.s           0.005         n.s
  Whole brain                 1.000           1.000           1.000           ---                 ---           ---           ---
  GM                          0.582 ± 0.005   0.580 ± 0.005   0.584 ± 0.005   0.131 (0.877)       n.s           n.s           n.s
  WM                          0.418 ± 0.005   0.420 ± 0.005   0.416 ± 0.005   0.131 (0.877)       n.s           n.s           n.s
  WMab                        0.010 ± 0.002   0.003 ± 0.002   0.002 ± 0.002   7.509 (0.001)       0.006         0.003         n.s
  Thalamus volumetry          0.013 ± 0.000   0.014 ± 0.000   0.013 ± 0.000   1.661 (0.199)       n.s           n.s           n.s
  Thalamus GM                 0.378 ± 0.026   0.475 ± 0.028   0.433 ± 0.028   3.251 (0.046)       0.041         n.s           n.s
  Thalamus WM                 0.610 ± 0.026   0.516 ± 0.027   0.559 ± 0.028   3.107 (0.052)       0.047         n.s           n.s
  Thalamus GMab               0.012 ± 0.001   0.009 ± 0.001   0.009 ± 0.001   4.337 (0.017)       0.036         n.s           n.s
  Caudate volumetry           0.010 ± 0.000   0.009 ± 0.000   0.008 ± 0.000   12.714 (0.000)      n.s           \<0.001       0.029
  Caudate GM                  0.843 ± 0.012   0.893 ± 0.013   0.876 ± 0.013   4.228 (0.019)       0.018         n.s           n.s
  Caudate WM                  0.141 ± 0.012   0.095 ± 0.012   0.113 ± 0.013   3.682 (0.031)       0.028         n.s           n.s
  Caudate GMab                0.016 ± 0.001   0.011 ± 0.001   0.011 ± 0.001   5.442 (0.007)       0.019         0.019         n.s
  Putamen volumetry           0.013 ± 0.000   0.013 ± 0.000   0.013 ± 0.000   1.637 (0.203)       n.s           n.s           n.s
  Putamen GM                  0.568 ± 0.028   0.631 ± 0.029   0.569 ± 0.030   1.584 (0.214)       n.s           n.s           n.s
  Putamen WM                  0.417 ± 0.027   0.362 ± 0.029   0.425 ± 0.029   1.415 (0.251)       n.s           n.s           n.s
  Putamen GMab                0.015 ± 0.003   0.007 ± 0.003   0.006 ± 0.003   2.919 (0.062)       n.s           n.s           n.s
  Global pallidus volumetry   0.004 ± 0.000   0.004 ± 0.000   0.004 ± 0.000   2.763 (0.071)       n.s           n.s           n.s
  Globus pallidus GM          0.098 ± 0.015   0.087 ± 0.016   0.087 ± 0.016   0.154 (0.858)       n.s           n.s           n.s
  Globus pallidus WM          0.889 ± 0.017   0.903 ± 0.018   0.907 ± 0.019   0.287 (0.752)       n.s           n.s           n.s
  Globus pallidus GMab        0.014 ± 0.005   0.010 ± 0.005   0.006 ± 0.005   0.658 (0.522)       n.s           n.s           n.s

CSF = cerebrospinal fluid; GM = gray matter; WM = white matter; WMab = white matter lesion load; GMab = deep gray nuclear lesion load; n.s = not significant.

Except for CSF, which is expressed as a fraction of total‐intracranial volume; all other values are expressed as fractions of volumes as detailed in the Methods section.

![Graphical depiction of thalamic and caudate **(a)** tissue compositions, **(b)** volumetry with comparisons between groups, and **(c)** area under the ROC curve for composite model predicting PIGD classification as 0.84.](JMRI-51-748-g002){#jmri26887-fig-0002}

Univariate regressions (Table [3](#jmri26887-tbl-0003){ref-type="table"}) against volumetric data, controlling for age and gender, demonstrated strong statistical significance of WMab, caudate, putamen, and thalamic GMab, and lateral and third ventricular volumes in predicting TBS scores (*P* \< 0.005) in both PIGD and PD. However, regression with a stepwise variable selection method performed on the whole cohort on an initial set of significant variables from univariate regressions showed that caudate GM was the single variable that significantly predicted TBS scores (b = 3.93, t(58) = 2.450, *P* = 0.017) and also explained 22% of the variance in TBS scores, *R* ^2^ = 0.22, *F*(5,58) = 3.26, *P* = 0.01, when adjusted for age and gender. ROC analysis (Fig. [2](#jmri26887-fig-0002){ref-type="fig"}c) of a model incorporating WMab, caudate GMab, and caudate GM discriminated PIGD with sensitivity = 0.83 and specificity = 0.76 (AUC = 0.84). This structural composite model may aid clinical differentiation of PIGD from PD. Table [4](#jmri26887-tbl-0004){ref-type="table"} shows the binary classification results for PIGD and the non‐PIGD group.

###### 

Selected Univariate Analysis of Dependence of TBS on Segmented Brain Structures, Controlling for Age and Gender in PIGD and PD

  Structure                   Unstandardized beta   Standardized beta   *P* value for unstandardized beta                  R^2^
  --------------------------- --------------------- ------------------- -------------------------------------------------- -------
  CSF                         --0.575               --0.293             0.034[\*](#jmri26887-note-0011){ref-type="fn"}     0.156
  Lateral ventricles          --123.511             --0.410             0.003[\*](#jmri26887-note-0011){ref-type="fn"}     0.220
  3^rd^ Ventricle             --2737.742            --0.424             0.002[\*](#jmri26887-note-0011){ref-type="fn"}     0.220
  4^th^ Ventricle             --2447.636            --0.316             0.013[\*](#jmri26887-note-0011){ref-type="fn"}     0.180
  GM                          12.544                0.055               0.687                                              0.093
  WM                          --12.544              --0.055             0.687                                              0.093
  WMab                        --274.422             --0.399             0.001[\*](#jmri26887-note-0011){ref-type="fn"}     0.235
  Thalamus volumetry          347.466               0.057               0.659                                              0.093
  Thalamus GM                 11.110                0.264               0.044[\*](#jmri26887-note-0011){ref-type="fn"}     0.150
  Thalamus WM                 --10.883              --0.256             0.051                                              0.147
  Thalamus GMab               --530.621             --0.342             0.005[\*](#jmri26887-note-0011){ref-type="fn"}     0.204
  Caudate volumetry           --2432.866            --0.550             \<0.001[\*](#jmri26887-note-0011){ref-type="fn"}   0.319
  Caudate GM                  29.248                0.322               0.014[\*](#jmri26887-note-0011){ref-type="fn"}     0.178
  Caudate WM                  --28.068              --0.298             0.023[\*](#jmri26887-note-0011){ref-type="fn"}     0.166
  Caudate GMab                --398.252             --0.366             0.003[\*](#jmri26887-note-0011){ref-type="fn"}     0.216
  Putamen volumetry           --767.086             --0.166             0.235                                              0.111
  Putamen GM                  0.368                 0.009               0.947                                              0.090
  Putamen WM                  1.405                 0.034               0.801                                              0.091
  Putamen GMab                --143.504             --0.360             0.003[\*](#jmri26887-note-0011){ref-type="fn"}     0.216
  Globus pallidus volumetry   257.412               0.015               0.913                                              0.090
  Globus pallidus GM          --6.393               --0.079             0.535                                              0.096
  Globus pallidus WM          6.771                 0.096               0.448                                              0.099
  Globus pallidus GMab        --28.150              --0.108             0.403                                              0.101

CSF = cerebrospinal fluid; GM = gray matter; WM = white matter; WMab = white matter lesion load; GMab = deep gray nuclear lesion load.

Significant *P* values \<0.05

###### 

Binary Multivariate Classification Results for PIGD and Non‐PIGD (including HC) Subjects in Relation to TBS Scores

  Classification rule   AUC     SEN     SPE     BACC    PPV     NPV     LP+     LR--    DeLong\'s test   McNemar test
  --------------------- ------- ------- ------- ------- ------- ------- ------- ------- ---------------- --------------
  WMab only             0.753   0.696   0.810   0.753   0.800   0.708   3.652   0.376   0.038            0.221
  Caudate GM only       0.670   0.435   0.905   0.670   0.833   0.594   4.565   0.625   0.017            0.001
  Caudate GMab only     0.671   0.913   0.429   0.671   0.636   0.818   1.598   0.203   0.001            0.008
  Combined              0.840   0.826   0.762   0.794   0.792   0.800   3.470   0.228                    

The following performance measures are reported: SEN = sensitivity; SPE = specificity; BACC = balanced accuracy (average of sensitivity and specificity); PPV = positive predictive value; NPV = negative predictive value; LR+ = positive likelihood ratio; LR-- = negative likelihood ratio. *P*‐values are reported for DeLong\'s and McNemar tests (with combined model as reference).

Discussion {#jmri26887-sec-0020}
==========

Volumetric findings of the caudate correlate well with severity of gait imbalance in PIGD, but less so with PD. The decrease in caudate gray matter represents a loss of dopaminergic terminals in a key relay nucleus downstream from the substantia nigra in the nigrostriatal pathway.[26](#jmri26887-bib-0026){ref-type="ref"} Compared with controls, caudate volumes were increased in our PD and PIGD patients, reflecting greater global brain atrophy relative to the caudate, as also reported by others.[27](#jmri26887-bib-0027){ref-type="ref"} Striatal atrophy has been reported to occur early in the disease and plateauing thereafter.[10](#jmri26887-bib-0010){ref-type="ref"}, [28](#jmri26887-bib-0028){ref-type="ref"}, [29](#jmri26887-bib-0029){ref-type="ref"} However, we found no significant atrophy of the putamen in our patients, which may be due to variations in morphometric methodology and patient populations.

Apart from neuronal loss in the striatum, white matter abnormalities are known to affect postural stability and gait motor functions in PD[30](#jmri26887-bib-0030){ref-type="ref"}, [31](#jmri26887-bib-0031){ref-type="ref"} by disrupting important subcortical afferents,[30](#jmri26887-bib-0030){ref-type="ref"} corticostriatal--thalamocortical loops,[32](#jmri26887-bib-0032){ref-type="ref"} and interhemispheric connections of the corpus callosum,[15](#jmri26887-bib-0015){ref-type="ref"}, [33](#jmri26887-bib-0033){ref-type="ref"} which are critical for complex integrated motor programs. This is particularly true for periventricular white matter abnormalities, which are known to be more prevalent in PIGD than in PD and HC.[28](#jmri26887-bib-0028){ref-type="ref"}, [30](#jmri26887-bib-0030){ref-type="ref"} Further research is needed to investigate how periventricular white matter lesions and caudate abnormalities increase disruption to the neuromodulator projection systems, with greater adverse impact on gait and balance motor scores.

To date, most PD‐related morphometric studies have focused on regional gray matter volume changes using a voxel‐based morphometry approach.[10](#jmri26887-bib-0010){ref-type="ref"}, [12](#jmri26887-bib-0012){ref-type="ref"}, [14](#jmri26887-bib-0014){ref-type="ref"}, [34](#jmri26887-bib-0034){ref-type="ref"} However, classification performance from a multivariate volume‐based morphometric approach has shown comparable or superior results over whole‐brain voxel‐based morphometry approaches[24](#jmri26887-bib-0024){ref-type="ref"} in neurodegenerative disorders. In addition, our approach incorporated lesional WMab in the whole‐brain analysis, accounting for periventricular white matter abnormalities, which are important pathological substrates in PIGD.[28](#jmri26887-bib-0028){ref-type="ref"}, [31](#jmri26887-bib-0031){ref-type="ref"}, [35](#jmri26887-bib-0035){ref-type="ref"}

Segmentation of GMab revealed differential involvement in our study groups. GMab is conceived as a T~1~ hypointense component within the deep gray matter nuclei anatomical masks and represents neuronal changes or degeneration with loss of dopaminergic terminals. On balance of evidence, the statistical significance in GMab difference across all three subgroups, the high sensitivity of GMab in the ROC analysis and the improved discriminative power in the ROC analysis when GMab is included suggests that GMab is a significant contributor to the nigrostriatal pathway disruption[7](#jmri26887-bib-0007){ref-type="ref"} besides conventional caudate GM volumetry and WMab in PIGD. Further work needs to be done to validate and apply this GMab estimation approach to other neurological disorders that affect deep gray matter nuclei.

We acknowledge several limitations in this study. First, we are cognizant that precise fidelity in automated classification of periventricular white matter and deep gray nuclear lesions remains challenging.[36](#jmri26887-bib-0036){ref-type="ref"}, [37](#jmri26887-bib-0037){ref-type="ref"} For example, Fig. [1](#jmri26887-fig-0001){ref-type="fig"}d illustrates minor misclassification of periventricular white matter lesions and residual gliotic hypointensities partly due to their close proximity to the ventricles.[36](#jmri26887-bib-0036){ref-type="ref"}

Second, tissue classification of the deep gray nuclei into gray and white matter components can be further refined. At present, the atlas‐free tissue classification algorithms in MorphoBox use the signal intensity of the deep gray nucleus to determine the white matter component and then parcellate it into each basal ganglia structure using atlas‐based segmentation. The small volume of these deep gray nuclei makes them vulnerable to partial volume averaging from surrounding white matter. Furthermore, neuronal loss with aging may also contribute to the computed white matter component at the subcellular level. Nevertheless, we demonstrated good results with the fast segmentation that allowed group discrimination of PIGD, further supporting the concept that high standards of exactitude are probably not a prerequisite in morphometric disease classification[24](#jmri26887-bib-0024){ref-type="ref"} to aid the clinician in diagnosis. Notwithstanding, further multimodal segmentation approaches incorporating relevant sequences (eg, T~2~W or FLAIR) may offer promise to account for all brain lesions with improved accuracy.[37](#jmri26887-bib-0037){ref-type="ref"} Third, cognitive and neuropsychiatric symptoms were not evaluated in our study. Nevertheless, there were no significant differences in lobar volumetric analyses of WM and cortical GM volumetry in our results.

In conclusion, using a multivariate volume‐based morphometry algorithm to derive white matter and deep gray nuclear lesion load, differential neuronal loss in key relay nuclei and white matter circuitry identified and correlated with gait imbalance severity. This allowed differentiation of the PIGD motor subtype from PD. The speed and unbiased discriminative power of this fully automated segmentation algorithm offers potential as a complement to clinical assessments and may support diagnosis and stratification of PD patients into relevant subtypes for better disease management.
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